Literature DB >> 31335803

Cross-sectional analysis of cognitive function using multivariate normative comparisons in men with HIV disease.

Zheng Wang1, Samantha A Molsberry, Yu Cheng, Lawrence Kingsley, Andrew J Levine, Eileen Martin, Cynthia A Munro, Ann Ragin, Leah H Rubin, Ned Sacktor, Eric C Seaberg, James T Becker.   

Abstract

BACKGROUND: Prevalence estimates of cognitive impairment in HIV disease vary widely. Here we used multivariate normative comparison (MNC) with identify individuals with impaired cognition, and to compare the results with those using the Frascati and Gisslén criteria.
METHODS: The current project used data collected before October 2014 from bisexual/gay men from the Multicenter AIDS Cohort Study. A total of 2904 men (mean age 39.7 years, 52.7% seropositive) had complete data in six cognitive domains at their first neuropsychological evaluation. T-scores were computed for each domain and the MNC was applied to detect impairment among seronegative and seropositive groups.
RESULTS: The MNC classified 6.26% of seronegative men as being impaired using a predetermined 5% false discovery rate. By contrast, the Frascati and the Gisslén criteria identified 24.54 and 11.36% of seronegative men as impaired. For seropositive men, the percentage impairment was 7.45, 25.73, and 11.69%, respectively, by the MNC, Frascati and Gisslén criteria. When we used seronegative men without medical comorbidities as the control group, the MNC, the Frascati and the Gisslén criteria identified 5.05, 27.07, and 4.21% of the seronegative men, and 4.34, 30.95, and 4.48% of the seropositive men as having cognitive impairment. For each method, serostatus was not associated with cognitive impairment.
CONCLUSION: The MNC controls the false discovery rate and therefore avoids the low specificity that characterizes the Frascati and Gisslén criteria. More research is needed to evaluate the sensitivity of the MNC method in a seropositive population that may be sicker and older than the current study sample and that includes women.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31335803      PMCID: PMC6832818          DOI: 10.1097/QAD.0000000000002312

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  28 in total

1.  Effect of ageing on neurocognitive function by stage of HIV infection: evidence from the Multicenter AIDS Cohort Study.

Authors:  Karl Goodkin; Eric N Miller; Christopher Cox; Sandra Reynolds; James T Becker; Eileen Martin; Ola A Selnes; David G Ostrow; Ned C Sacktor
Journal:  Lancet HIV       Date:  2017-07-14       Impact factor: 12.767

2.  The early neurologic signs and symptoms of HIV infection.

Authors:  James T Becker
Journal:  Neurology       Date:  2016-06-10       Impact factor: 9.910

3.  The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center.

Authors:  R K Heaton; I Grant; N Butters; D A White; D Kirson; J H Atkinson; J A McCutchan; M J Taylor; M D Kelly; R J Ellis
Journal:  J Int Neuropsychol Soc       Date:  1995-05       Impact factor: 2.892

4.  Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Authors:  L P Jacobson; R Li; J Phair; J B Margolick; C R Rinaldo; R Detels; A Muñoz
Journal:  Am J Epidemiol       Date:  2002-04-15       Impact factor: 4.897

Review 5.  The age-dependent relation of blood pressure to cognitive function and dementia.

Authors:  Chengxuan Qiu; Bengt Winblad; Laura Fratiglioni
Journal:  Lancet Neurol       Date:  2005-08       Impact factor: 44.182

6.  Multivariate normative comparisons.

Authors:  Hilde M Huizenga; Harriet Smeding; Raoul P P P Grasman; Ben Schmand
Journal:  Neuropsychologia       Date:  2007-03-23       Impact factor: 3.139

7.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants.

Authors:  R A Kaslow; D G Ostrow; R Detels; J P Phair; B F Polk; C R Rinaldo
Journal:  Am J Epidemiol       Date:  1987-08       Impact factor: 4.897

8.  Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study.

Authors:  L A Kingsley; R Detels; R Kaslow; B F Polk; C R Rinaldo; J Chmiel; K Detre; S F Kelsey; N Odaka; D Ostrow
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

9.  Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection.

Authors:  Bing Sun; Linda Abadjian; Hans Rempel; Alexander Monto; Lynn Pulliam
Journal:  J Acquir Immune Defic Syndr       Date:  2013-02-01       Impact factor: 3.731

10.  Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings.

Authors:  K Blackstone; D J Moore; D R Franklin; D B Clifford; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; R J Ellis; J H Atkinson; I Grant; R K Heaton
Journal:  Clin Neuropsychol       Date:  2012-06-18       Impact factor: 3.535

View more
  8 in total

1.  Using HIV neuropsychological classification methods to predict employment status.

Authors:  David E Vance; James T Becker
Journal:  AIDS       Date:  2021-09-01       Impact factor: 4.632

2.  Reductions in Gray Matter Linked to Epigenetic HIV-Associated Accelerated Aging.

Authors:  Brandon J Lew; Mikki D Schantell; Jennifer O'Neill; Brenda Morsey; Tina Wang; Trey Ideker; Susan Swindells; Howard S Fox; Tony W Wilson
Journal:  Cereb Cortex       Date:  2021-07-05       Impact factor: 5.357

3.  Longitudinal 5-year prediction of cognitive impairment among men with HIV disease.

Authors:  Natalia L Oliveira; Edward H Kennedy; Ryan Tibshirani; Andrew Levine; Eileen Martin; Cynthia Munro; Ann B Ragin; Leah H Rubin; Ned Sacktor; Eric C Seaberg; Andrea Weinstein; James T Becker
Journal:  AIDS       Date:  2021-05-01       Impact factor: 4.177

4.  Legacy effect on neuropsychological function in HIV-infected men on combination antiretroviral therapy.

Authors:  Yang Qu; Andrea Weinstein; Zheng Wang; Yu Cheng; Lawrence Kingsley; Andrew Levine; Eileen Martin; Cynthia Munro; Ann B Ragin; Leah H Rubin; Ned W Sacktor; Eric C Seaberg; James T Becker
Journal:  AIDS       Date:  2022-01-01       Impact factor: 4.177

5.  Quantifying diagnostic accuracy improvement of new biomarkers for competing risk outcomes.

Authors:  Zheng Wang; Yu Cheng; Eric C Seaberg; James T Becker
Journal:  Biostatistics       Date:  2020-02-21       Impact factor: 5.279

6.  Longitudinal multivariate normative comparisons.

Authors:  Zheng Wang; Yu Cheng; Eric C Seaberg; Leah H Rubin; Andrew J Levine; James T Becker
Journal:  Stat Med       Date:  2020-12-09       Impact factor: 2.497

7.  Rates of cognitive impairment in a South African cohort of people with HIV: variation by definitional criteria and lack of association with neuroimaging biomarkers.

Authors:  Anna J Dreyer; Sam Nightingale; Jodi M Heaps-Woodruff; Michelle Henry; Hetta Gouse; Robert H Paul; Kevin G F Thomas; John A Joska
Journal:  J Neurovirol       Date:  2021-07-09       Impact factor: 2.643

Review 8.  Studying the neuropsychological sequelae of SARS-CoV-2: lessons learned from 35 years of neuroHIV research.

Authors:  Andrew Levine; Ned Sacktor; James T Becker
Journal:  J Neurovirol       Date:  2020-09-03       Impact factor: 2.643

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.